Literature DB >> 19258855

Survival probabilities of patients with childhood spinal muscle atrophy.

Mohannad M Mannaa1, Maninder Kalra, Brenda Wong, Aliza P Cohen, Raouf S Amin.   

Abstract

OBJECTIVE: Medical and technological advances over the past 2 decades have resulted in improved patient care for children with spinal muscular atrophy (SMA). The objective of the present study was to describe changes in the life expectancy of pediatric patients with SMA over time and to compare these findings with previously reported survival patterns.
METHODS: Medical records of all patients diagnosed with SMA over a 16-year period (1989-2005) at Cincinnati Children's Hospital Medical Center were reviewed. Data pertaining to date of birth, type of SMA, medical and surgical interventions, pulmonary complications, and date of death were obtained.
RESULTS: Kaplan-Meier survival analyses showed a significant improvement in survival probabilities in the severest form of SMA.
CONCLUSIONS: We found a positive trend in the survival of patients with severe SMA. Although we cannot attribute this trend to any single factor, it is likely that advances in pulmonary care and aggressive nutritional support have played a significant role.

Entities:  

Mesh:

Year:  2009        PMID: 19258855     DOI: 10.1097/CND.0b013e318190310f

Source DB:  PubMed          Journal:  J Clin Neuromuscul Dis        ISSN: 1522-0443


  13 in total

1.  Demographic characteristics of SMA type 1 patients at a tertiary center in Turkey.

Authors:  Barış Ekici; Betül Bozkurt; Burak Tatlı; Mine Calışkan; Nur Aydınlı; Meral Ozmen
Journal:  Eur J Pediatr       Date:  2011-10-21       Impact factor: 3.183

2.  Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.

Authors:  Santiago Zuluaga-Sanchez; Megan Teynor; Christopher Knight; Robin Thompson; Thomas Lundqvist; Mats Ekelund; Annabelle Forsmark; Adrian D Vickers; Andrew Lloyd
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

3.  Spinal muscular atrophy type 1: are proactive respiratory interventions associated with longer survival?

Authors:  Tara J Lemoine; Kathryn J Swoboda; Susan L Bratton; Richard Holubkov; Michael Mundorff; Rajendu Srivastava
Journal:  Pediatr Crit Care Med       Date:  2012-05       Impact factor: 3.624

4.  Nutritional practices at a glance: spinal muscular atrophy type I nutrition survey findings.

Authors:  Rebecca Hurst Davis; Barbara J Godshall; Erin Seffrood; Mary Marcus; Bernard A LaSalle; Brenda Wong; Mary K Schroth; Kathryn J Swoboda
Journal:  J Child Neurol       Date:  2013-10-04       Impact factor: 1.987

Review 5.  Bone health and associated metabolic complications in neuromuscular diseases.

Authors:  Nanette C Joyce; Lauren P Hache; Paula R Clemens
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-10-17       Impact factor: 1.784

6.  Survival analysis of spinal muscular atrophy type I.

Authors:  Hyun Bin Park; Soon Min Lee; Jin Sung Lee; Min Soo Park; Kook In Park; Ran Namgung; Chul Lee
Journal:  Korean J Pediatr       Date:  2010-11-30

7.  Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States.

Authors:  Cathy Lally; Cynthia Jones; Wildon Farwell; Sandra P Reyna; Suzanne F Cook; W Dana Flanders
Journal:  Orphanet J Rare Dis       Date:  2017-11-28       Impact factor: 4.123

8.  New insights into SMA pathogenesis: immune dysfunction and neuroinflammation.

Authors:  Marc-Olivier Deguise; Rashmi Kothary
Journal:  Ann Clin Transl Neurol       Date:  2017-05-18       Impact factor: 4.511

Review 9.  Emerging therapies and challenges in spinal muscular atrophy.

Authors:  Michelle A Farrar; Susanna B Park; Steve Vucic; Kate A Carey; Bradley J Turner; Thomas H Gillingwater; Kathryn J Swoboda; Matthew C Kiernan
Journal:  Ann Neurol       Date:  2017-02-17       Impact factor: 10.422

10.  Evaluation of peripheral blood mononuclear cell processing and analysis for Survival Motor Neuron protein.

Authors:  Dione T Kobayashi; Douglas Decker; Phillip Zaworski; Karen Klott; Julie McGonigal; Nabil Ghazal; Laurel Sly; Brett Chung; James Vanderlugt; Karen S Chen
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.